GlassScriptPhysician profile
Catherine Molly Kohl
NPI 1801370812
$11,321.14
in general payments reported to CMS, 2019-2025
30 companies · $2,483 in 2025
The $2,483 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,595 · 2022: $2,478 · 2023: $2,697 · 2024: $2,067 · 2025: $2,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,054 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,053.68 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,551.72 | 2021-2025 | |
| Amgen INC. | $1,645.68 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Glaxosmithkline, LLC. | $959.54 | 2021-2025 | Benlysta |
| Pfizer INC. | $906.45 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $898.11 | 2021-2025 | Acthar |
| Ucb, INC. | $834.56 | 2021-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $817.52 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $606.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $355.18 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $302.05 | 2021-2025 | Orencia, Cobenfy |
| Lilly USA, LLC | $276.73 | 2021-2024 | Taltz |
| Ani Pharmaceuticals, INC. | $269.45 | 2022-2024 | Purified Cortrophin Gel |
| Radius Health, INC. | $236.23 | 2023-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $126.98 | 2022-2025 | Strensiq |
| Sobi, INC | $110.62 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.00 | 2021 | |
| Genzyme Corporation | $50.39 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $29.42 | 2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.34 | 2024 | Cyltezo |
| Hikma Pharmaceuticals USA | $28.09 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $25.32 | 2024 | Arcalyst |
| Ultragenyx Pharmaceutical INC. | $24.15 | 2023 | |
| Kyowa Kirin, INC. | $22.19 | 2025 | |
| Tersera Therapeutics LLC | $20.00 | 2022 | |
| Fresenius Kabi USA, LLC | $18.60 | 2024 | Idacio |
| Organon LLC | $18.36 | 2024 | |
| Csl Behring | $17.00 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $14.91 | 2022 | |
| Genentech USA, INC. | $14.53 | 2024 | Actemra |
| Kiniksa Pharmaceuticals, LTD. | $13.13 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Kohl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.